

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
"Handing exclusive rights to publicly-funded vaccines and medicines to just a few companies simply does not work—for rich countries or poorer ones," said an adviser to the People's Vaccine Alliance.
Vaccine equity campaigners on Monday condemned European Union nations for hoarding Covid-19 vaccine doses at the expense of low-income countries after a new Politico analysis estimated that the bloc's members have thrown out at least €4 billion—roughly $4.4 billion—worth of the lifesaving shots.
That equates to around 215 million coronavirus vaccine doses—very likely an undercount, given that Politico wasn't able to obtain waste numbers from every E.U. member country.
"Calculations based on available data show that E.U. countries have discarded an average of 0.7 jabs for every member of their population," the outlet reported. "Top of the scale is Estonia, which binned more than one dose per inhabitant, followed closely by Germany, which also threw away the largest raw volume of jabs."
Piotr Kolczyński, E.U. health policy adviser at the People's Vaccine Alliance and Oxfam International, said in a statement that the new analysis is "further proof that the E.U. wasted millions of its Covid-19 vaccines, hoarded early in the pandemic, as it locked poorer countries out of access."
"The appalling waste in the world's pandemic response was disastrous," said Kolczyński. "Handing exclusive rights to publicly-funded vaccines and medicines to just a few companies simply does not work—for rich countries or poorer ones."
Politico attributed much of the waste to the E.U.'s massive 2021 deal with Pfizer and BioNTech, which agreed to sell 1.1 billion doses of their mRNA jab to members of the bloc as low-income countries struggled to obtain shots for their populations.
"Despite considering a significant reform to reign in pharmaceutical waste and profiteering within its borders, the EU fails to support similar efforts on the global stage."
E.U. members—Germany in particular—pushed back aggressively against the India and South Africa-led call for a Covid-19 vaccine patent waiver, which proponents said would have lifted key barriers to expanding vaccine manufacturing and access. Germany alone has wasted 83 million vaccine doses, according to Politico.
The pharmaceutical industry, for its part, lobbied aggressively to preserve its monopoly control over vaccine recipes and production, focusing significant attention on the European Commission.
With the global health emergency formally over, countries are currently negotiating the terms of a pandemic agreement that would govern how the international community responds to the next global crisis.
Reuters reported in September that "governments remain divided, failing to agree on some of the basics needed to strengthen health systems worldwide."
"Those basics, all issues that hindered a coordinated global response to the Covid-19 outbreak, include the sharing of information, costs, and vaccines," Reuters added. "The divisions arose anew in June, when the European Union negotiated new agreements with pharmaceutical companies to reserve vaccines for future pandemics. The agreements led critics to accuse the bloc of 'vaccine apartheid.'"
Last month, 18 members of the European Parliament wrote to the Council of the European Union and the European Commission expressing "concerns about the E.U.'s negotiating position."
"It proposes to continue relying solely on voluntary measures in the deployment of key public health interventions, such as the transfer of technology, know-how and 'trade secrets,' or the removal of intellectual property barriers," the lawmakers wrote. "In the meantime, the E.U. avoids specific commitments for equitable access to pandemic products."
As the People's Vaccine Alliance noted Monday, the E.U.'s latest proposed text "suggests removing transparency and equity measures."
"Despite considering a significant reform to reign in pharmaceutical waste and profiteering within its borders, the E.U. fails to support similar efforts on the global stage," said Kolczyński. "It is one rule for the E.U. and another for everyone else."
"Public funding delivers incredible medical advances and that should be a priority for all countries, but pharmaceutical companies cannot be trusted to share technology with the world."
Scientists Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine on Monday for research that paved the way for the messenger RNA vaccines against Covid-19—critical work that, as campaigners quickly pointed out, benefited from substantial U.S. government funding.
Dr. Mohga Kamal-Yanni, policy co-lead for the People's Vaccine Alliance, said in a statement that "this award challenges the claim that it was solely big pharmaceutical companies who saved the world from Covid-19."
"Just like the Oxford-AstraZeneca vaccine, Karikó and Weissman's groundbreaking work on mRNA vaccines received a huge amount of public funding," said Kamal-Yanni. "Pharmaceutical companies have refused to share mRNA technologies with developers and researchers in developing countries."
The Nobel Prize committee credited Karikó and Weissman with fundamentally changing "our understanding of how mRNA interacts with our immune system."
"The laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times," the committee said.
As The Washington Post summarized, the pair "discovered how to chemically tweak messenger RNA, turning basic biology into a technology ready to change the world when the pandemic struck. Their discovery is incorporated into the coronavirus vaccines made by Moderna and Pfizer and its German partner, BioNTech, which have now been given billions of times."
But the Post and other major outlets covering Karikó and Weissman's Nobel prize-winning contributions did not emphasize—or even mention—that some of the scientists' work was funded by the National Institutes of Health. Karikó and Weissman patented their findings in 2006 and later licensed the patents to Moderna and BioNTech, Pfizer's coronavirus vaccine partner.
According to an analysis by Knowledge Ecology International (KEI), Weissman "appears as the principal investigator on a total of 42 projects funded by the National Institutes of Health (NIH) between 1998 and 2020, representing $18,323,060 in costs."
"Karikó was the principal investigator of four projects funded by the NIH between 2007 and 2011, totaling $1,234,462 in costs," KEI observed. "In other words, the United States government funded and has certain rights over at least some of the foundational Karikó and Weissman patents directed to mRNA discoveries."
"As governments discuss how to prepare for the next pandemic, they should learn from the story of mRNA."
Throughout the pandemic and into the present, vaccine makers such as Pfizer and Moderna have opposed global calls to share their vaccine recipes and technology with the world, fiercely clinging to their monopoly control over production and using that control to force governments into one-sided contracts favorable to the pharmaceutical industry—even though their vaccines were developed with massive public support.
A
study published in The BMJ earlier this year estimated that the U.S. government pumped nearly $32 billion into the development, production, and purchase of mRNA coronavirus vaccines.
The Biden administration, meanwhile, has declined to use its ownership of key patents or the leverage provided by public funding to force pharmaceutical companies to do everything they can to ensure the equitable distribution of lifesaving vaccine technology.
Kamal-Yanni of the People's Vaccine Alliance said Monday that "fortunately, Weissman is helping a WHO-backed mRNA program which aims to develop mRNA technology in lower-income countries, even while pharmaceutical companies refuse to share their know-how."
"As governments discuss how to prepare for the next pandemic, they should learn from the story of mRNA," said Kamal-Yanni. "Public funding delivers incredible medical advances and that should be a priority for all countries, but pharmaceutical companies cannot be trusted to share technology with the world."
Peter Maybarduk, director of the Access to Medicines program at Public Citizen, echoed that message, saying in a statement that "today's Nobel must ring as a call for equity and health justice, and a call to change a massively unjust pharmaceutical industry."
"Moderna, Pfizer, and BioNTech still largely control the available vaccines and in some countries have significantly increased their price, despite the billions in public funding on which the vaccines rely," said Maybarduk. "By supporting initiatives to share science and technology, and by funding vaccine infrastructure, governments can help blunt the effects of disease, and bring a coda of justice to a terribly unjust time."
This story has been updated to include a statement from Public Citizen.
"The global response to Covid-19 failed the world's most vulnerable, prioritizing windfall profits ahead of public health," said one expert, calling on world leaders to "make structural changes in global health."
The World Health Organization's declaration Friday that Covid-19 is no longer a global health emergency elicited fresh calls for learning from the pandemic and dramatically expanding access to prevention and treatment for diseases in the future.
"Covid-19 may no longer be classified as the highest level of international emergency, but the virus has not gone away," said Dr. Mohga Kamal-Yanni, policy co-lead of the People's Vaccine Alliance, a global coalition working toward equitable access to medical technologies that help to prevent and respond to Covid-19 and future pandemics.
"There are billions of people in developing countries who still cannot access affordable Covid-19 tests and treatments," Kamal-Yanni stressed. "They need action from governments to remove the intellectual property barriers that prevent the widespread production of generic medicines."
"Rich countries behaved shamefully in this pandemic, upholding pharmaceutical monopolies and grabbing vaccines, tests, and medicines for their people, pushing developing countries to the back in the line."
WHO Director-General Tedros Adhanom Ghebreyesus said Friday that while the agency has documented almost 7 million deaths from the virus, "we know the toll is several times higher—at least 20 million." A study published last year in Nature and cited by the People's Vaccine Alliance estimates that 1.3 million fewer people would have died by the end of 2021 if Covid-19 vaccines were equitably distributed.
"Rich countries behaved shamefully in this pandemic, upholding pharmaceutical monopolies and grabbing vaccines, tests, and medicines for their people, pushing developing countries to the back in the line," said Kamal-Yanni. "And pharmaceutical companies are the biggest winners, achieving the biggest profit from a single medical product in history, while people died without access."
Ahead of the WHO announcement but in the wake of the annual general meetings of Johnson & Johnson, Merck, Moderna, and Pfizer, Amnesty International health adviser Tamaryn Nelson on Thursday lamented that the pharmaceutical giants declined to "right their wrongs" by passing resolutions to facilitate the universal distribution of Covid-19 vaccines.
"For the past three years, those at the helm of Big Pharma companies have seen earnings soar, while people in low- and lower-middle-income countries are still struggling to access lifesaving medicines," Nelson noted. "While their efforts to speedily develop Covid-19 vaccines should be recognized, it's clear pharmaceutical companies have failed in their human rights responsibilities when it comes to ensuring equal access—and continue to do so. Why aren't investors holding them to account?"
"With reports that Pfizer and Moderna are considering quadrupling the price of each Covid-19 vaccine in some countries, only 25% of people in low-income countries are now fully vaccinated and millions are still waiting for the first dose," she continued, calling the allocation of the shots "one of the worst examples of global inequality to date."
According to Nelson, "It's time for investors to ensure these companies are making structural changes with immediate effect to ensure the world can withstand future pandemics collectively, without leaving anyone behind."
Kamal-Yanni argued that tackling future crises will require more actively involving people from lower-income nations.
"The institutions set up to support developing countries, like COVAX and ACT-A, failed to involve developing countries in their creation or decision-making, and failed to deliver an equitable response," she said. "For future pandemics, preparation and response must be led by the Global South, instead of creating more global platforms dominated by donors."
"People in developing countries should never again wait for the 'good will' of rich countries, nor charitable actions of pharmaceutical companies," she asserted. "The world needs transformative commitments in the Pandemic Treaty and International Health Regulations to ensure knowledge and technology are shared, remove intellectual property barriers, and to support medical research and manufacturing in developing countries."
Negotiators aim to finalize a draft of the Pandemic Treaty for consideration by the 77th World Health Assembly in 2024.
"Just as with HIV, the global response to Covid-19 failed the world's most vulnerable, prioritizing windfall profits ahead of public health," said Kamal-Yanni. "World leaders must now learn from the last three years, and make structural changes in global health. Or else, we are doomed to repeat the mistakes of this pandemic in the next."
Dr. Uché Blackstock, a former emergency medicine professor who works to end bias and racism in healthcare, tweeted Friday that "it's truly unfortunate that both domestically and globally, other than vaccines—which I'm truly grateful to science for—there have been no significant improvement/investments in our public health infrastructure to keep people and their communities safe."
The Covid-19 crisis could have led to massive investments in health workers, workplace protections, and paid leave, Blackstock said in response to the WHO announcement. The United States could have shifted to universal healthcare and joined other nations of the Global North in promoting vaccine equity.
"It felt like THIS was our opportunity to do better!!" she added, also circulating a graphic shared by Dr. Madhu Pai showing that the 2.3 billion people who remain unvaccinated against Covid-19 are largely concentrated in low- and middle-income countries.
Pai also pointed to an "important" piece published Thursday in Science titled "Cascading Failures in Covid-19 Vaccine Equity."
Noting that "the proliferation of equity rhetoric does not appear to be matched by corresponding rates of progress in reducing global disparities," a trio of U.S.-based experts wrote for Science that "the stark gap between the pervasive rhetoric about equity and the dismal reality of the global vaccine distribution" the past three years "demands a collective reckoning."
"Expansive rhetoric and empty promises have surprising staying power," they added. "If we wish equity to have anything more than allegorical value, we must take the concept more seriously, beginning with a disciplined and deliberate examination of the equity-deficit cascade."
As Common Dreams reported throughout the Covid-19 crisis, experts have warned that preventing future pandemics requires not only improvements in healthcare systems but also global land use reforms—from conservation efforts to changes in agricultural practices—to stop the spillover of diseases from animals to humans.
"These past three years should act as a warning for future pandemics," said former U.N. Secretary-General Ban Ki-moon. "We need a return to genuine cooperation between nations in our preparation and response to global threats."
Around 200 current and former world leaders, Nobel laureates, health and faith leaders, and activists this week marked the third anniversary of the World Health Organization's Covid-19 pandemic declaration by taking aim at the "vaccine apartheid" that according to one advocacy group was responsible for one death every 24 seconds during the outbreak's first year alone.
A letter led by the People's Vaccine Alliance notes that three years have passed since "the World Health Organization (WHO) first characterized Covid-19 as a pandemic" on March 11, 2020 and implores governments to "never again" allow nationalism and capitalist greed to supersede human needs."
"We have seen extraordinary feats of scientific innovation and an enormous mobilization of public resources to develop effective vaccines, tests, and treatments," the letter continues. "But we have also seen a global response held back by profiteering and nationalism."
The signers asserted:
We are hopeful that an end to the acute stage of the Covid-19 pandemic may be in sight. Thus, the world is at a critical juncture. Decisions made now will determine how the world prepares for and responds to future global health crises. World leaders must reflect on mistakes made in responding to the Covid-19 pandemic so that they are never repeated.
There are decades of publicly funded research behind Covid-19 vaccines, treatments, and tests. Governments have poured taxpayer money by the billions into research, development, and advance orders, reducing the risks for pharmaceutical companies. These are the people's vaccines, the people's tests, and the people's treatments. Yet, a handful of pharmaceutical companies has been allowed to exploit these public goods to fuel extraordinary profits, increasing prices in the Global North while refusing to share technology and knowledge with capable researchers and producers in the Global South.
"Instead of rolling out vaccines, tests, and treatments based on need, pharmaceutical companies maximized their profits by selling doses first to the richest countries with the deepest pockets," the letter adds. "Billions of people in low- and middle-income countries, including frontline workers and the clinically vulnerable, were sent to the back of the line."
These inequities, the alliance said, resulted in over 1.3 million preventable deaths—one every 24 seconds—in the pandemic's first year alone. Even today, as the pandemic enters its fourth year, much of the Global South lacks adequate access to Covid-19 testing and treatments.
The letter's signatories urge world leaders to take immediate action to:
"In the AIDS pandemic, pharmaceutical monopolies have resulted in an appalling number of unnecessary deaths—and it has been the same story with Covid-19," lamented Winnie Byanyima, executive director of UNAIDS and co-chair of the People's Vaccine Alliance.
"It was only the production of inexpensive generics in developing countries that made the first generation of HIV medicines available and affordable to people in the [Global] South," she added. "But governments still have not learned that lesson. Unless they break the monopolies that prevent people from accessing medical products, humanity will sleepwalk unprepared into the next pandemic."
East Timorese President José Manuel Ramos-Horta, who also signed the letter, said that "in the Covid-19 pandemic, those of us in low and middle-income countries were pushed to the back of the line for vaccines and denied access to the benefits of new technologies."
"Three years on, we must say 'never again' to this injustice that has undermined the safety of people in every country," he added. "Steps that we take today can hasten global access to vaccines, medicines, and tests in the next pandemic, with regional hubs researching, developing, and manufacturing medical products for everyone, everywhere."
Former United Nations Secretary-General Ban Ki-moon asserted:
The great tragedy of the Covid-19 pandemic has been the failure of multilateralism and the absence of solidarity between the Global North and Global South. These past three years should act as a warning for future pandemics. We need a return to genuine cooperation between nations in our preparation and response to global threats. That requires a pandemic accord rooted in equity and human rights, which places the needs of humanity above the commercial interests of a handful of companies.
Independent Panel for Pandemic Preparedness and Response co-chair Helen Clark—who served as New Zealand's prime minister from 1999 to 2008—noted that "publicly funded science contributed a lot to the phenomenal success of Covid-19 vaccines."
"Yet, that public investment did not lead to vaccines being treated as global common goods," Clark continued. "Rather, nationalism and profiteering around vaccines resulted in a catastrophic moral and public health failure which denied equitable access to all."
"We need to fix the glaring gaps in pandemic preparedness and response today," she added, "so that people in all countries can be protected when a pandemic threat emerges."
One advocate said Moderna's windfall was a "direct result of the company’s refusal to share vaccine technology with the Global South, even when it was clear that global shortages would be deadly."
The Massachusetts-based pharmaceutical giant Moderna announced Thursday that it brought in over $19 billion in revenue and $8.4 billion in profits in 2022 thanks primarily to its Covid-19 vaccine, which was made possible by federal funding and government technology.
"U.S. taxpayers and people all over the world should be furious," Maaza Seyoum, Global South convenor of the People's Vaccine Alliance, said in response to Moderna's earnings report. "It was built on decades of publicly funded research into mRNA vaccines. And it was developed in partnership with the U.S. National Institutes of Health. This should be the people's vaccine, available and affordable to everyone, everywhere, not a goldmine for Big Pharma."
“Moderna's revenue in 2022 alone is equivalent to the combined health budgets of 68 countries," Seyoum noted. "Already, the company expects to make more from the vaccine in 2023 than the combined health budgets of 42 countries." As CNBC reported, "Moderna has contracts on the books for $5 billion in Covid vaccine deliveries for 2023."
Moderna sold $18.4 billion worth of its coronavirus vaccine—the company's only product on the market—last year while rejecting calls to share critical technology with the rest of the world, denying low-income countries the ability to quickly produce lifesaving shots for their populations.
Tim Bierley, a pharma campaigner at the U.K.-based advocacy group Global Justice Now, said Thursday that "history will not be kind to Moderna, whose scandalous profits are a direct result of the company's refusal to share vaccine technology with the Global South, even when it was clear that global shortages would be deadly."
"Millions of people around the world are now grieving the loss of family members, many of whom were unable to get a Covid-19 vaccine," said Bierley. "Moderna's pandemic profiteering is even more shocking given that the U.S. public-funded 100% of this vaccine's development. Now the company is brazenly threatening to hike prices on its vaccine—but governments should refuse to be held to ransom. And well before the next pandemic, we must make sure that taxpayer money comes with conditions that put lives above profits."
Moderna's earnings announcement came weeks after the company sparked widespread backlash by proposing to hike the U.S. price of its coronavirus vaccine by 4,000% over the cost of production.
Among those who condemned the planned price hike was Sen. Bernie Sanders of Vermont, who has used his platform as chair of the Senate Health, Education, Labor, and Pensions Committee to call out Moderna and other pharmaceutical giants for exploiting health crises to pad their bottom lines.
Shortly after Sanders announced last week that he intends to grill Moderna's billionaire CEO on the vaccine price during a Senate hearing next month, the company said it would ensure its shot remains available for free in the U.S.
"This is an astounding reversal, entirely due to Bernie Sanders preparing to make Moderna a poster child of corporate greed, along with the public organizing against the company," said Robert Weissman, president of the consumer advocacy group Public Citizen.
"Put simply, Pfizer has plundered health systems for profit," said the People's Vaccine Alliance.
The U.S.-based pharmaceutical giant Pfizer reported Tuesday that it brought in a record-breaking $100.3 billion in revenue in 2022 and $31.4 billion in profit, sums that campaigners decried as "sickening" in the face of an ongoing pandemic and persistent inequities in coronavirus vaccine access.
"In one year alone, Pfizer's revenue has exceeded the total health expenditures of more than 100 countries combined," Julia Kosgei, policy co-lead for the People's Vaccine Alliance, said in a statement. "If it were a country, Pfizer would sit in the wealthiest third of nation-states. And it has amassed this fortune while jacking up prices on Covid-19 vaccines amid a pandemic that has devastated people’s livelihoods. Put simply, Pfizer has plundered health systems for profit."
Pfizer, led by CEO Albert Bourla, is the manufacturer of one of the two available mRNA vaccines for Covid-19, as well as the oral coronavirus treatment Paxlovid. The company reported $56 billion in sales of its Covid-19 vaccine and Paxlovid, though it said it expects sales to drop in the coming year as it moves to hike prices significantly on its vaccine—a plan that has drawn international alarm and outrage.
Globally, more than 2,600 people are dying from Covid-19 each day on average. According to Our World in Data, just over 26% of people in low-income nations have received at least one coronavirus vaccine dose as Pfizer and other pharmaceutical giants refuse to make their vaccine technology available to all—even though it was developed with the help of government funding and scientific advancements.
"Billions of people in developing countries still cannot access affordable Covid-19 medicines," said Kosgei. "Companies like Pfizer are gobbling up ever-greater proportions of health budgets and handing the spoils to wealthy shareholders—all while treating access for developing countries as little more than a PR initiative. We cannot go on like this."
The U.K.-based advocacy group Global Justice Now called Pfizer's record earnings report "sickening."
"With this latest 'all-time high' announcement, Pfizer now has revenues higher than the GDP of 133 countries, including 8 E.U. member states, and is the first pharma company ever to make $100 billion in a year," noted Tim Bierley, the group's pharma campaigner. "But not content with doubling its revenues with a pandemic windfall, they are now still moving to aggressively hike the price of Covid-19 booster doses, putting even more pressure on already struggling public health systems."
"Their latest record-breaking revenues are further proof that the company treated the pandemic as an opportunity to enrich its shareholders," Bierley added. "We can't allow Big Pharma companies to hold us to ransom in this way. We need the government to be bold and break with the monopoly patent model that fails people everywhere. It's time to put people's lives above corporate profit."
"A people-funded vaccine should be cheap and freely available."
Both Pfizer and Moderna have signaled plans to raise the prices of their vaccines to somewhere between $110 to $130 per dose in the U.S. as the Biden administration moves ahead with the commercialization of coronavirus inoculations, tests, and treatments—shifting costs onto patients and insurers and leaving the uninsured to shoulder significant payments.
The U.S. government has previously paid around $30 per dose for Pfizer's vaccine.
In recent days, the Biden administration has faced growing calls to use the federal government's ownership of key patents and other leverage to force Moderna and Pfizer to make their vaccines affordable and readily available to all who want them.
"The Biden administration should not allow Moderna to more than quadruple the price of the Covid vaccine to $130 when it costs just $2.85 to produce," Sen. Bernie Sanders (I-Vt.) tweeted on Sunday. "The Covid vaccine must be used to save lives, not to further enrich the billionaire owners of Moderna."
Moderna and Pfizer are also facing backlash from lawmakers overseas over their planned price increases.
In a letter to Bourla and Moderna CEO Stéphane Bancel on Tuesday, British MP Caroline Lucas of the Green Party and three other lawmakers wrote that with the National Health Service "already under significant pressure and the costs of medicines increasing year on year, we are extremely concerned about the multiple impacts of a possible price hike."
"Throughout its development, the Pfizer/BioNTech vaccine received huge amounts of public money and support internationally," the lawmakers wrote. "Even the mRNA technology that Pfizer/BioNTech employed in the Covid-19 vaccine is rooted in decades of publicly funded research. A people-funded vaccine should be cheap and freely available."
"At a time when online mobilizations were one of the few forms of protest available to the public, Twitter was seemingly asked to shield the powerful from criticism," said one campaigner. "That should worry all those who care about accountability."
Drugmaker BioNTech and the German government pushed Twitter to "hide" posts by activists calling on Big Pharma to temporarily lift patents on Covid-19 vaccines—a move which would have given people the Global South greater access to the lifesaving inoculations, a report published Monday by The Intercept revealed.
Twitter lobbyist Nina Morschhaeuser "flagged the corporate accounts of Pfizer, BioNTech, Moderna, and AstraZeneca for her colleagues to monitor and shield from activists," according to The Intercept's Lee Fang. An email from Morschhaeuser said the German Federal Office for Information Security also contacted Twitter on behalf of BioNTech, whose spokesperson, Jasmina Alatovic, asked the social media giant to "hide" activist tweets targeting her company's account for two days.
Morschhaeuser, meanwhile, requested that colleagues track the hashtags #PeoplesVaccine—a movement for the temporary lifting of patent protections—and #JoinCTAP, a reference to the World Health Organization's Covid-19 Technology Access Pool. Morschhaeuser further warned that the advocacy group Global Justice Now shared an online signup form for a December 2020 People's Vaccine Day of Action.
"The allegations in this article suggest that government and industry tried to silence legitimate criticism during a crisis," Maaza Seyoum, Global South convener at the People's Vaccine Alliance, said in a statement Monday. "At a time when online mobilizations were one of the few forms of protest available to the public, Twitter was seemingly asked to shield the powerful from criticism. That should worry all those who care about accountability."
Global Justice Now director Nick Dearden also noted the troubling timing of BioNTech's censorship request during a period of global pandemic lockdowns.
"To try and stifle digital dissent during a pandemic, when tweets and emails are some of the only forms of protest available to those locked in their homes, is deeply sinister," he told The Intercept.
Fang writes:
It is not clear to what extent Twitter took any action on BioNTech's request. In response to Morschhaeuser's inquiry, several Twitter officials chimed in, debating what action could or could not be taken. Su Fern Teo, a member of the company's safety team, noted that a quick scan of the activist campaign showed nothing that violated the company's terms of service, and asked for more examples to "get a better sense of the content that may violate our policies."
But it shows the extent to which pharmaceutical giants engaged in a global lobbying blitz to ensure corporate dominance over the medical products that became central to combating the pandemic. Ultimately, the campaign to share Covid vaccine recipes around the world failed.
While U.S. President Joe Biden in 2021 heeded activists' calls and joined most of the Global South in backing a Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver at the World Trade Organization, most rich nations—including Germany—oppose the policy and have, along with Big Pharma, fought to thwart it.
"If the German government wants to show that it is now willing to side with public health over private profit, it must change its approach to pandemic response," Seyoum asserted. "That means backing efforts at the World Trade Organization to improve access to generic Covid-19 medicines and treatments, supporting the World Health Organization's mRNA Hub in South Africa, and standing up to corporate interests in negotiations over a Pandemic Treaty."
Global health campaigners denounced U.S. President Joe Biden's administration for refusing to support a temporary suspension of patents for Covid-19 tests and treatments this year, a move that further delays the possibility of securing a World Trade Organization intellectual property waiver aimed at increasing access to lifesaving medical tools in developing nations.
In a statement released on Tuesday morning, U.S. Trade Representative Katherine Tai said that "over the past five months, USTR officials held robust and constructive consultations with Congress, government experts, a wide range of stakeholders, multilateral institutions, and WTO members."
Tai continued:
Real questions remain on a range of issues, and the additional time, coupled with information from the USITC [United States International Trade Commission], will help the world make a more informed decision on whether extending the ministerial decision to Covid-19 therapeutics and diagnostics would result in increased access to those products. Transparency is critical and USTR will continue to consult with Congress, stakeholders, and others as we continue working to end the pandemic and support the global economic recovery.
As Bloomberg reported, investigations of the sort that Tai wants the USITC to pursue "can take nine months to a year to complete," pushing the prospects for a comprehensive waiver of the WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) well into 2023 or beyond.
Dr. Mohga Kamal-Yanni, policy co-lead for the People's Vaccine Alliance, said in response that "it is heartbreaking to see the Biden administration succumb to pressure from pharmaceutical company lobbyists and their henchmen in Congress."
"This moment of weakness will cost countless lives in low- and middle-income countries, leading to continued economic devastation."
"This moment of weakness will cost countless lives in low- and middle-income countries, leading to continued economic devastation," said Kamal-Yanni, "while a handful of pharmaceutical CEOs and shareholders will get even richer."
"The U.S. has had more than two years to meaningfully engage in WTO negotiations over access to lifesaving tests and treatments," she added. "Kicking the issue further into the long grass, just as the negotiating deadline approaches, is pathetic."
This sentiment was echoed by Arthur Stamoulis, executive director of the Trade Justice Education Fund.
"There have been at least 290,000 deaths from Covid-19 since the WTO punted on the question of global access to tests and treatments back in June," said Stamoulis. "How many more need to die before the U.S. joins the right side of history?"
"We're in the third year of the pandemic and billions of people worldwide still don't have access to Covid tests, vaccines, and medicines," Stamoulis continued.
Large swaths of the Global South have been deprived of lifesaving Covid-19 medical tools and remain completely unprotected, with less than 25% of people in low-income countries having received at least one vaccine dose to date.
Experts have long argued that pausing enforcement of the corporate-friendly TRIPS Agreement for the duration of the pandemic would remove the intellectual property barriers standing in the way of increased generic manufacturing. However, in June, Big Pharma-aligned policymakers--most of them from highly vaccinated rich countries--defeated a popular proposal to waive coronavirus-related patents to boost the global supply of jabs, diagnostics, and therapeutics.
Instead, the WTO, which operates on the consensus of its 164 members, adopted a watered-down alternative pertaining only to vaccines--described by critics as worse than the status quo--and vowed to decide whether to extend the decision to cover tests and treatments within six months. The Biden White House's new demand for a delay--in which they joined the European Union, United Kingdom, Japan, South Korea, Singapore, and Switzerland--comes just days before the December 17 deadline.
As Knowledge Ecology International director James Love pointed out on social media, the U.S. government blocked the proposed TRIPS waiver for tests and treatments after telling the World Health Organization that it is opposed to including intellectual property flexibilities in an emerging WHO pandemic treaty "because that's a conversation for the WTO."
Meanwhile, the need for improved access to tests and treatments is particularly acute in poor countries, given the ongoing severity of global vaccine apartheid.
The WHO estimates that just one in every 50 tests is administered in low- and middle-income nations home to 84% of the global population. While publicly available data on treatment access is sparse, a recent analysis from Oxfam and the People's Vaccine Alliance shows that just a quarter of Pfizer's Paxlovid pill orders are destined for developing countries.
Pfizer's licensing agreement with the United Nations-backed Medicines Patent Pool enables other drugmakers to produce its pill for generic consumption in just 95 countries representing 53% of the global population. As a result, excluded countries, many of which are not wealthy, may be forced to pay $250 per course rather than $25.
Globally, the ongoing Covid-19 pandemic has caused more than 15 million deaths directly and indirectly, and the disease alone continues to kill roughly 1,500 people per day.
The profoundly inequitable allocation of medicines--fueled by high-income nations snatching up a disproportionate share of vaccines, tests, and treatments and pharmaceutical corporations refusing to share knowledge and technology--has exacerbated avoidable suffering. Artificially imposed scarcity and uneven distribution also enables the coronavirus to continue circulating and mutating, increasing the likelihood of a vaccine-resistant variant emerging.
A recent investigation revealed the extent to which Big Pharma has lobbied against a robust intellectual property waiver for Covid-19 jabs, diagnostics, and therapeutics--and worsened deadly inequality in the process.
Tai's "call for 'more information' cannot be an excuse for inaction," Stamoulis said Tuesday. "While pharmaceutical monopolies make billions, people are still dying, others are getting long Covid, the economy is suffering, and new variants remain a constant threat."
"It's long past time," he added, "for the Biden administration to support the modest changes to WTO pharmaceutical monopoly protections standing in the way of Covid test and treatment access around the world."